Reminder for uniQure Shareholders on Class Action
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy QURE?
Source: Globenewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased uniQure ordinary shares between September 24, 2025, and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to potentially receive compensation without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that uniQure failed to fully disclose FDA approval for its pivotal study on Huntington's disease treatment, resulting in investor losses when the true information was revealed, highlighting significant transparency issues within the company.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its successful track record and expertise, urging investors to select qualified legal counsel wisely.
- Investor Action Steps: Investors can visit the Rosen Law Firm website or call the toll-free number for more information on how to participate in the lawsuit, ensuring they receive the necessary legal support and potential compensation in the class action.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QURE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QURE
Wall Street analysts forecast QURE stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 17.140
Low
33.00
Averages
49.88
High
70.00
Current: 17.140
Low
33.00
Averages
49.88
High
70.00
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
uniQure Faces Severe Rebuke from FDA Amid Class Action Lawsuit
- FDA Rebuke: An FDA official publicly labeled uniQure's AMT-130 gene therapy candidate as a 'failed therapy,' accusing the company of conducting a 'distorted or manipulated comparison' in clinical studies, which could undermine investor confidence in the company's future prospects.
- Surgical Requirement Controversy: The FDA official dismissed uniQure's ethical concerns regarding 'sham surgeries,' clarifying that the agency did not request 'drilling holes in skulls' but rather 'one to three nicks in the scalp' under minimal anesthesia, potentially impacting the design and implementation of the company's clinical trials.
- Legal Action Update: The securities class action against uniQure alleges that the company failed to disclose that the FDA had not approved the use of the ENROLL-HD external historical data set as a primary control for AMT-130, which may lead to diminished investor trust in the company's transparency.
- Critical Deadline: Investors must apply to be Lead Plaintiff by April 13, 2026, or risk losing the opportunity to represent their interests in the lawsuit, further affecting their investment decisions.
See More
uniQure Investors File Class Action Lawsuit Over FDA Approval Delay
- Deadline for Filing: Investors in uniQure N.V. must submit lead plaintiff applications by April 13, 2026, to participate in a securities class action lawsuit concerning shares purchased between September 24 and October 31, 2025, highlighting significant investor concern over corporate transparency.
- Stock Price Plunge: Following the FDA's delay in approving AMT-130, uniQure's stock price plummeted by $33.40, or over 49%, from $67.69 to $34.29 on November 3, 2025, reflecting extreme market pessimism regarding the company's future prospects.
- Legal Accountability Claims: uniQure and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, indicating serious deficiencies in the company's information disclosure practices that could erode investor trust.
- Legal Consultation Availability: Investors seeking to understand their legal rights and the potential impact of this case on their economic losses can contact KSF law firm, demonstrating the company's commitment to investor rights and the necessity of legal support.
See More
uniQure Faces Severe FDA Rebuke Amid Class Action
- FDA Rebuke: On March 5 and 6, 2026, an FDA official publicly criticized uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy,' alleging the company engaged in 'distorted or manipulated comparisons' in clinical studies, which significantly undermines the company's reputation and investor confidence.
- Securities Class Action: Hagens Berman is investigating uniQure for failing to disclose critical interactions with the FDA during the class period from September 24 to October 31, 2025, which has left investors facing substantial losses and is expected to negatively impact the company's stock price.
- Critical Deadline: Investors must apply to be Lead Plaintiff in the class action by April 13, 2026, and failure to act promptly may result in lost claims, further affecting uniQure's market performance and investor sentiment.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to utilize the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery, potentially increasing the legal risks faced by uniQure as more witnesses may come forward to support the investigation.
See More
uniQure N.V. Shareholder Files Class Action Lawsuit
- Class Action Initiated: A shareholder has filed a securities class action lawsuit on behalf of investors who purchased uniQure N.V. (NASDAQ: QURE) shares between September 24, 2025, and October 31, 2025, alleging misrepresentations regarding the drug AMT-130, which may have led to investor losses.
- Legal Procedure Details: Investors wishing to serve as lead plaintiff must file papers by April 13, 2026, with the lead plaintiff representing other class members in the litigation, although one can still share in any recovery without being the lead.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times in The National Law Journal’s “Plaintiffs’ Hot List” for its success in litigating hundreds of class actions, highlighting its influence in the legal field.
- Transparent Fee Structure: All representation by the law firm is on a contingency fee basis, meaning shareholders incur no fees or expenses, ensuring fair treatment for all investors involved in the legal proceedings.
See More
Reminder for uniQure Shareholders on Class Action Lawsuit
- Class Action Notification: Rosen Law Firm reminds investors who purchased uniQure ordinary shares between September 24, 2025, and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that uniQure misrepresented the approval status of its pivotal study for Huntington's disease treatment and downplayed the likelihood of delays in its Biologics License Application, which negatively impacted investor confidence in the company's prospects.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first by ISS for the number of securities class action settlements in 2017, highlighting its expertise in this field.
- Participation Instructions: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, ensuring they select qualified legal counsel to protect their interests, even though the class has not yet been certified, allowing for the option to remain absent or inactive.
See More
uniQure Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against uniQure N.V., aiming to recover damages for investors who purchased the company's securities between September 24 and October 31, 2025, reflecting strong investor response to potential violations.
- Detailed Allegations: The complaint alleges that uniQure and its executives made materially false statements regarding the company's business and operations, failing to disclose critical facts related to FDA approvals, which could mislead investors about the company's prospects and undermine market confidence.
- BLA Submission Delay Risk: The lawsuit highlights that despite purportedly successful results from the Pivotal Study, uniQure may need to delay its Biologics License Application (BLA) timeline to conduct additional studies, which could negatively impact the company's financing and market performance.
- Investor Rights Opportunity: Affected investors must apply to be lead plaintiffs by April 13, 2026, with the law firm promising to charge fees only upon successful recovery, demonstrating a commitment to protecting investor rights.
See More
uniQure Faces Severe Rebuke from FDA Amid Class Action Lawsuit
- FDA Rebuke: An FDA official publicly labeled uniQure's AMT-130 gene therapy candidate as a 'failed therapy,' accusing the company of conducting a 'distorted or manipulated comparison' in clinical studies, which could undermine investor confidence in the company's future prospects.
- Surgical Requirement Controversy: The FDA official dismissed uniQure's ethical concerns regarding 'sham surgeries,' clarifying that the agency did not request 'drilling holes in skulls' but rather 'one to three nicks in the scalp' under minimal anesthesia, potentially impacting the design and implementation of the company's clinical trials.
- Legal Action Update: The securities class action against uniQure alleges that the company failed to disclose that the FDA had not approved the use of the ENROLL-HD external historical data set as a primary control for AMT-130, which may lead to diminished investor trust in the company's transparency.
- Critical Deadline: Investors must apply to be Lead Plaintiff by April 13, 2026, or risk losing the opportunity to represent their interests in the lawsuit, further affecting their investment decisions.
See More
uniQure Investors File Class Action Lawsuit Over FDA Approval Delay
- Deadline for Filing: Investors in uniQure N.V. must submit lead plaintiff applications by April 13, 2026, to participate in a securities class action lawsuit concerning shares purchased between September 24 and October 31, 2025, highlighting significant investor concern over corporate transparency.
- Stock Price Plunge: Following the FDA's delay in approving AMT-130, uniQure's stock price plummeted by $33.40, or over 49%, from $67.69 to $34.29 on November 3, 2025, reflecting extreme market pessimism regarding the company's future prospects.
- Legal Accountability Claims: uniQure and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, indicating serious deficiencies in the company's information disclosure practices that could erode investor trust.
- Legal Consultation Availability: Investors seeking to understand their legal rights and the potential impact of this case on their economic losses can contact KSF law firm, demonstrating the company's commitment to investor rights and the necessity of legal support.
See More
uniQure Faces Severe FDA Rebuke Amid Class Action
- FDA Rebuke: On March 5 and 6, 2026, an FDA official publicly criticized uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy,' alleging the company engaged in 'distorted or manipulated comparisons' in clinical studies, which significantly undermines the company's reputation and investor confidence.
- Securities Class Action: Hagens Berman is investigating uniQure for failing to disclose critical interactions with the FDA during the class period from September 24 to October 31, 2025, which has left investors facing substantial losses and is expected to negatively impact the company's stock price.
- Critical Deadline: Investors must apply to be Lead Plaintiff in the class action by April 13, 2026, and failure to act promptly may result in lost claims, further affecting uniQure's market performance and investor sentiment.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to utilize the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery, potentially increasing the legal risks faced by uniQure as more witnesses may come forward to support the investigation.
See More
uniQure N.V. Shareholder Files Class Action Lawsuit
- Class Action Initiated: A shareholder has filed a securities class action lawsuit on behalf of investors who purchased uniQure N.V. (NASDAQ: QURE) shares between September 24, 2025, and October 31, 2025, alleging misrepresentations regarding the drug AMT-130, which may have led to investor losses.
- Legal Procedure Details: Investors wishing to serve as lead plaintiff must file papers by April 13, 2026, with the lead plaintiff representing other class members in the litigation, although one can still share in any recovery without being the lead.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times in The National Law Journal’s “Plaintiffs’ Hot List” for its success in litigating hundreds of class actions, highlighting its influence in the legal field.
- Transparent Fee Structure: All representation by the law firm is on a contingency fee basis, meaning shareholders incur no fees or expenses, ensuring fair treatment for all investors involved in the legal proceedings.
See More
Reminder for uniQure Shareholders on Class Action Lawsuit
- Class Action Notification: Rosen Law Firm reminds investors who purchased uniQure ordinary shares between September 24, 2025, and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that uniQure misrepresented the approval status of its pivotal study for Huntington's disease treatment and downplayed the likelihood of delays in its Biologics License Application, which negatively impacted investor confidence in the company's prospects.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first by ISS for the number of securities class action settlements in 2017, highlighting its expertise in this field.
- Participation Instructions: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, ensuring they select qualified legal counsel to protect their interests, even though the class has not yet been certified, allowing for the option to remain absent or inactive.
See More
uniQure Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against uniQure N.V., aiming to recover damages for investors who purchased the company's securities between September 24 and October 31, 2025, reflecting strong investor response to potential violations.
- Detailed Allegations: The complaint alleges that uniQure and its executives made materially false statements regarding the company's business and operations, failing to disclose critical facts related to FDA approvals, which could mislead investors about the company's prospects and undermine market confidence.
- BLA Submission Delay Risk: The lawsuit highlights that despite purportedly successful results from the Pivotal Study, uniQure may need to delay its Biologics License Application (BLA) timeline to conduct additional studies, which could negatively impact the company's financing and market performance.
- Investor Rights Opportunity: Affected investors must apply to be lead plaintiffs by April 13, 2026, with the law firm promising to charge fees only upon successful recovery, demonstrating a commitment to protecting investor rights.
See More
